In addition, CD8+/PD-1+/CD28− T cells from non-small cell lung cancer (NSCLC) patients showed a lower response to anti-PD-1 treatment as compared to CD8+/PD-1+/CD28+ T cells [52]. Here, CD28 is linked to non-small cell lung carcinoma.